Evaluate erenumab- aooe efficacy as a therapeutic approach, for the management of painful
chronic temporomandibular disorders (TMD).
The study will be a randomized, double blind, placebo-controlled trial comparing
erenumab-aooe vs Placebo.
A total of 60 patients (30 per each arm) aged 18-65 years old of either sex, and any race or
ethnicity presenting chronic temporomandibular disorders (TMD), (meeting the Diagnostic
Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications of
chronic TMD (myalgia +/- arthralgia) will be randomly assigned in a 1:1 parallel,
double-blind clinical trial, to receive either erenumab-aooe or placebo. Participants will
attend 6 clinic visits (Visit 0-Visit 5) over a period of 21 weeks (20 +/- 1 weeks). Changes
in pain intensity and other pain outcomes related to TMD will be assessed. Blood samples will
be collected, and participants will need to keep a daily symptom diary and answer some other
questionnaires.